Patents by Inventor Sudip Chakrabortty

Sudip Chakrabortty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATMENT USING BCN057 AND BCN512
    Publication number: 20230035771
    Abstract: The present disclosure is directed to methods of treating or ameliorating various conditions by the administration of a BCN057, BCN512 or analogs of these compounds. The compounds can be used to reduce tumor burden in cancers, including pancreatic cancer and gastrointestinal (GI) cancer. The compounds can also be used to protect against chemotherapy induced toxicity to the GI tract. Further, they can be used to treat fibrosis and various inflammatory conditions. Analogs of BCN057 and BCN512 are also described.
    Type: Application
    Filed: June 13, 2022
    Publication date: February 2, 2023
    Applicant: BCN Biosciences L.L.C.
    Inventors: Andrew J. Norris, Sudip Chakrabortty
  • Methods of treatment using BCN057 and BCN512
    Patent number: 11358964
    Abstract: The present disclosure is directed to methods of treating or ameliorating various conditions by the administration of a BCN057, BCN512 or analogs of these compounds. The compounds can be used to reduce tumor burden in cancers, including pancreatic cancer and gastrointestinal (GI) cancer. The compounds can also be used to protect against chemotherapy induced toxicity to the GI tract. Further, they can be used to treat fibrosis and various inflammatory conditions. Analogs of BCN057 and BCN512 are also described.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: June 14, 2022
    Assignee: BCN Biosciences L.L.C.
    Inventors: Andrew J. Norris, Sudip Chakrabortty
  • METHODS OF TREATMENT USING BCN057 AND BCN512
    Publication number: 20210053968
    Abstract: The present disclosure is directed to methods of treating or ameliorating various conditions by the administration of a BCN057, BCN512 or analogs of these compounds. The compounds can be used to reduce tumor burden in cancers, including pancreatic cancer and gastrointestinal (GI) cancer. The compounds can also be used to protect against chemotherapy induced toxicity to the GI tract. Further, they can be used to treat fibrosis and various inflammatory conditions. Analogs of BCN057 and BCN512 are also described.
    Type: Application
    Filed: August 24, 2020
    Publication date: February 25, 2021
    Applicant: BCN Biosciences L.L.C.
    Inventors: Andrew J. Norris, Sudip Chakrabortty